Standout Papers
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015)
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes (2016)
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus (2016)
- How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017)
- Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease (2019)
- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial (2019)
Immediate Impact
1 by Nobel laureates 1 from Science/Nature 64 standout
Citing Papers
Gliflozins in the Management of Cardiovascular Disease
2022 Standout
Non-alcoholic fatty liver disease
2021 Standout
Works of David Fitchett being referenced
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| David Fitchett | 5737 | 6610 | 12416 | 198 | 18.0k | |
| Odd Erik Johansen | 3700 | 6166 | 14296 | 118 | 17.1k | |
| Mikhail Kosiborod | 8746 | 4140 | 11596 | 422 | 20.9k | |
| Helen M. Colhoun | 4058 | 7813 | 8596 | 273 | 18.6k | |
| Marc P. Bonaca | 6514 | 5664 | 6800 | 273 | 14.6k | |
| Ofri Mosenzon | 3395 | 4655 | 12734 | 140 | 15.1k | |
| Uli C. Broedl | 4102 | 8994 | 18132 | 117 | 22.4k | |
| François Cambien | 9863 | 3130 | 6881 | 229 | 20.4k | |
| David Z.I. Cherney | 2776 | 4801 | 10214 | 323 | 14.1k | |
| Janet B. McGill | 2913 | 3347 | 8767 | 230 | 15.6k | |
| Michaela Mattheus | 2810 | 4754 | 11062 | 80 | 13.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...